Please login to the form below

Not currently logged in
Email:
Password:

IL-13 inhibitor

This page shows the latest IL-13 inhibitor news and features for those working in and with pharma, biotech and healthcare.

AZ, Amgen’s first-in-class asthma drug gets breakthrough status

AZ, Amgen’s first-in-class asthma drug gets breakthrough status

AZ, Amgen’ s first-in-class asthma drug gets breakthrough status. The IL-5 inhibitor is already approved for severe asthma in the EU. ... Regeneron’s new candidate Dupixent (dupilumab), an IL-4 and IL-13 inhibitor that is already approved for atopic

Latest news

  • GSK sells eczema and psoriasis drug to Dermavant for £250m GSK sells eczema and psoriasis drug to Dermavant for £250m

    The cut included IL-6 inhibitor sirukumab for rheumatoid arthritis, which left tapinarof as the lead candidate in its immuno-inflammation programme. ... Meanwhile, in atopic dermatitis, Regeneron and Sanofi’s IL4/IL-13 inhibitor Dupixent (dupilumab)

  • AZ’s Fasenra hit by COPD trial failure AZ’s Fasenra hit by COPD trial failure

    Nucala was the first IL-5 inhibitor to reach the market in 2015, and made £344m ($465m) in sales last year. ... IL-13 inhibitor tralokinumab has been abandoned after three failed late-stage trials, however, while AZ also has an Amgen-partnered thymic

  • NICE rejects Sanofi’s Dupixent for atopic dermatitis at first call NICE rejects Sanofi’s Dupixent for atopic dermatitis at first call

    Despite the confidential discount on Dupixent’s list price of £1, 264.89 per pack of two syringes of the IL-4 and IL-13 inhibitor - developed with Regeneron - the cost

  • AZ gets EMA green light for severe asthma drug Fasenra AZ gets EMA green light for severe asthma drug Fasenra

    AstraZeneca has picked up an approval in the EU for its interleukin-5 inhibitor Fasenra in severe asthma, mirroring its US approval in this indication last November. ... Prospects for IL-13 inhibitor tralokinumab look terminal after three failed

  • AZ prices severe asthma drug Fasenra below competition AZ prices severe asthma drug Fasenra below competition

    The US FDA has approved AstraZeneca’s interleukin-5 inhibitor Fasenra for severe asthma, setting up a fight in the market with rival drugs from GlaxoSmithKline and Teva. ... Prospects for IL-13 inhibitor tralokinumab look rocky after two failed

More from news
Approximately 1 fully matching, plus 17 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Healthcare Media Europe – HME Ltd

HME are an innovative and technology enabled agency offering our clients over 35+ years of knowledge and expertise in delivering...

Latest intelligence

A reflection of ESMO
Client Relationship Director Fabienne Wild from Ashfield Meetings & Events reflects on the recent conference season and on her experience at the European Society for Medical Oncology (ESMO)....
OUTiCO win Best in UK Pharmaceutical Outsourcing award
The Corporate LiveWire Healthcare and Life Sciences Awards celebrate global companies and individuals who have excelled over the past 12 months....
artificial-intelligence-in-healthcare.jpg
Artificial Intelligence in Healthcare
Artificial intelligence is already out-diagnosing experts, but would you put a computer in charge of your healthcare? The good, the bad; we take a look....

Infographics